European Leukemia Trial Registry
Trial: AZA-MDS-003

More Details
Title Azacitidine Plus BSC vs Placebo Plus BSC in Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to Lower-risk MDS
Scientific Title A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes
Short Title AZA-MDS-003
Trialgroup Deutsche MDS
Type of Trial multicentric, randomized, prospective, double-blind, double-group
Disease Myelodysplastic Syndrome(MDS) Low risk and intermedia I
Age >= 18 years
Status Active
Start of Recruitment 01.02.2013
Leader Platzbecker, Prof. Dr. med., Uwe
Shortprotocol Shortprotocol
created 04.02.2013 Sina Hehn
changed 06.05.2013 Sina Hehn
ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org